Epitalon: what the research shows, and why no dose is published

What epitalon is

Epitalon (also written epithalon) is a synthetic four-amino-acid peptide — alanine, glutamic acid, aspartic acid, glycine, abbreviated AEDG. It was designed in Russia as a synthetic stand-in for epithalamin, a pineal-gland extract studied there from the 1970s onwards.

• It is not an approved medicine in the United States, the EU, the UK, Canada or Australia, and it does not appear in any pharmacopoeia monograph as a therapeutic product.
• Material sold online is supplied as a lyophilized research chemical, usually labeled 'not for human consumption'.
• Because it is unapproved, there is no regulated label, no verified strength and no manufacturing standard behind a typical vial.
• Most of the published work comes from one research group, which is a real limitation when reading the results.

What the research actually shows

The epitalon literature is dominated by cell-culture work and animal studies, with a small number of long-running Russian clinical reports that have not been replicated independently.

• In human somatic cell cultures, epitalon has been reported to induce telomerase activity and extend the number of divisions cells achieve. That is a laboratory observation in cells, not a demonstrated effect on human ageing.
• Rodent studies from the same group report effects on melatonin rhythm, tumour incidence and lifespan in specific strains; other laboratories have not repeated them at scale.
• The human reports are small, largely open-label, decades old and published mainly in Russian-language journals, so they do not meet the evidentiary bar used for approved medicines.
• There is no published, replicated pharmacokinetic profile in humans — meaning half-life, exposure and accumulation are not reliably characterized.

Why no dose is published here

The most common search around epitalon is a dose. There is no authoritative one to quote, and repeating a forum protocol as if it were a standard would be misleading.

• No regulator has ever approved a strength, a frequency or a course length for epitalon in humans.
• The numbers that circulate online trace back to study protocols in animals or to vendor marketing, not to a label.
• Because vial content is unverified, the same 'protocol' can mean very different actual exposures between suppliers.
• Anyone considering it should be doing so with a clinician who knows their history — that is the honest answer, not a cautious one.

Safety, testing and what to record

The practical risks with an unapproved injectable peptide are usually about the product, not the molecule.

• Sterility, endotoxin, net content and identity are all unverified in research-grade material. Independent testing is the only way to know what is in a vial.
• Reconstitution and cold-chain errors degrade peptides quietly — the vial looks the same either way.
• Interactions are unmapped: with no human pharmacology data, nobody can state confidently how it behaves alongside prescribed medicines.
• If you are tracking anything at all, record the supplier, lot, reconstitution volume, date opened and every dose, so an adverse effect can be traced rather than guessed at.

References

• Khavinson VKh, et al. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells (Bull Exp Biol Med 2003)
• Anisimov VN, Khavinson VKh. Peptide bioregulation of aging: results and prospects (Biogerontology 2010)
• FDA — Compounding and the FD&C Act: bulk drug substances nominated for compounding
• PubChem — Epitalon (AEDG tetrapeptide) compound record